SINGAPORE, MALAYSIA / ACCESSWIRE / June 29, 2018 / XinFin recently launched its integrated XDC protocol based Wallet product for diverse applications in trade and financing. XDC Wallet as a solution can be used by individuals, corporates, and financial institutions to facilitate internal as well as cross-border real-time settlement for business transactions, trade, financing, equity transaction settlement and remittances.

Built upon XinFin’s flagship hybrid blockchain network protocol, the XDC Wallet offers a plethora of attributes in terms of security and high throughput, coupled with low transaction fees as compared to other financial transaction media. This blockchain based wallet can be integrated into industrial areas with extended operations as well as with standalone businesses. XinFin provides the option to set up a Wallet on a Private blockchain with or without changing any current running systems to leverage blockchain based use cases.

The XDC blockchain wallet is designed exclusively keeping in mind real-world requirements, and it integrates the use of fiat currency and exchange of the token with the local fiat (as per the local law of the land), as well as other cryptocurrencies, in order to enable cross-platform and cross token payments.

XinFin’s Chris Neill says, “Instead of money, people can make payments using XDCE tokens at the counter and also cash in on the loyalty points and rewards they get by doing token based transactions. The XDC simplified wallet is the most viable solution for businesses on all peripherals encompassing small canteens to multi-chain restaurants, banks, organizations, stores, hotels, travel and online purchases, or any other transaction record trail required for the audit.”

XinFin has already built a use case on the XDC Wallet in the power sector. Digitization and IoT integration of the XDC Wallet triggers peer-to-peer wallet transfers between multiple parties towards payment and repayment.

XinFin offers the multisig feature with their wallet which increases its security. Besides using the digital asset, multisig requires multi-party or multi-user signatures in order to validate and implement the transaction. The XDC wallet can be used with any compliance system supported by local law or with any running ERP or SAP by simply accessing secure Wallet API.

About XinFin

XinFin is a global open source Hybrid Blockchain protocol/platform with independent community contributors comprising of long term backers, network utility and tech developers that help build various enterprise use-cases. XinFin Network [XDCE] (https://coinmarketcap.com/currencies/xinfin-network/) is a utility network that lets enterprises deploy real-world applications on a Hybrid Blockchain Protocol in a conducive, compliant and regulation-friendly environment for diverse use cases in trade, finance, remittance, supply chain, healthcare and other industrial areas, to improve business efficiency. XinFin’s hybrid blockchain network provides viability to host enterprise subnetworks on a permissioned and scalable environment for private transactions. The XDC Dev Environment encourages developers to build DAPPs using smart contracts. XDCE is listed on CoinMarketCap which promotes and provides a comparative study of tokens.

CONTACT:

Follow XinFin on Twitter: @XinFinF
Telegram https://t.me/xinfintalk
Slack https://xinfin-public.slack.com/
Contribute to their GitHub channel https://github.com/XinFinorg

SOURCE: XinFin

ReleaseID: 504157

LOS ANGELES, CA / ACCESSWIRE / June 29, 2018 / NMS 1759 offers the best in luxury apartment living anywhere in West Los Angeles. Located in the heart of the Sawtelle Japantown neighborhood, these apartments deliver unsurpassed convenience and indulgence. With a wide selection of flat, loft and townhouse-style units, these Los Angeles apartments offer something for everyone.

Professionally managed by NMS Residential, NMS 1759 is conveniently located near the 405 freeway and is only a short drive to a diverse selection of lively neighborhoods like Beverly Hills, Brentwood, and Santa Monica. UCLA and several large employers like Kroger Company and Bank of America are also nearby and an easy commute.

While considered a “boutique luxury style apartment building,” NMS 1759 still provides a number of amenities to its residents including available garage parking, controlled access entry to the building with intercom system and charging stations for electric and hybrid vehicles. In addition, there is bicycle storage, a conference room with media screen and a gorgeous oasis in the courtyard which features plush seating, water features, free Wi-Fi and plenty of greenery.

Pet owners are welcome as each apartment home is cat and dog friendly with certain breed restrictions. There is a refundable pet deposit and pet rent required.

Each apartment home at NMS 1759 is fully equipped with central cooling and heating, stainless steel kitchen appliances including a dishwasher, in-home washer and dryer set, polished granite countertops, and flooring made of tile and hardwood-style laminate with plush Berber carpeting in the bedrooms. Each unit is built for sound reduction with double paned glass windows.

Despite easy access to some of Los Angeles’s hottest spots, residents need not go far in order to find an eclectic collection of shops, markets, restaurants, and services: NMS 1759’s West Los Angeles apartments are situated less than a block from Sawtelle Boulevard’s bustling commercial district known as Sawtelle Japantown.

ABOUT NMS RESIDENTIAL

NMS Residential is a privately owned real estate management firm specialized in the professional management of upscale multifamily and mixed-use properties throughout the Greater Los Angeles area.

Led by a seasoned team of executives with multidisciplinary backgrounds, NMS Residential’s ever-expanding portfolio includes over 18 market rate properties located in Santa Monica, Westwood, Brentwood, the San Fernando Valley and beyond. Throughout our portfolio, we are committed to providing an exceptional living experience for our residents. Our communities feature thoughtful floor plans, exceptional amenities, and boutique-level services.

OUR COMMUNITIES

At NMS Residential, exceptional design, professional service, and luxury living are our highest priorities. Our commitment to quality is visible in everything that we do. That is because we don’t just manage apartments, we curate vibrant communities in desirable locations throughout Los Angeles.

From contemporary residences in Santa Monica to furnished apartments in Westwood, NMS Residential apartment buildings add character and prestige to their neighborhoods. Located in some of the most desirable areas in the county, our Los Angeles, and Santa Monica, CA apartments feature carefully crafted design, stunning interiors, luxury amenities, and top-quality finishes, to provide residents with an unparalleled lifestyle.

Explore our extensive portfolio to see why NMS Residential represents the new standard of Los Angeles apartment living.

SOURCE: NMS Residential

ReleaseID: 504179

BOSTON, MA / ACCESSWIRE / June 29, 2018 / Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors in Flex Pharma, Inc. (“Flex Pharma” or the “Company”) (NASDAQ: FLKS) that Monday, August 20, 2018 is the deadline to seek lead plaintiff status in the pending securities class action against the Company and certain of its officers and directors.

The lawsuit, filed in the Southern District of New York (No. 1:18-cv-05493), alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the viability and approval prospects for its product candidate FLX-787 for the treatment of ALS and CMT; and (ii) as a result, Flex Pharma’s public statements were materially false and misleading at all relevant times.

On June 13, 2018, Flex Pharma announced that it planned to halt both the COMMEND and the COMMIT trials (the trials connected to “FLX-787”), citing oral tolerability concerns observed in both studies. On this news, FLKS stock plunged about 75%.

If you purchased or otherwise acquired FLKS securities between November 6, 2017 and June 12, 2018 and have questions about your legal rights or possess information relevant to this investigation, you are encouraged to contact Attorney John DeFelice at (888) 868-2385, by email at john@blockesq.com or by visiting http://shareholder.law/flks.

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nations’ largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
John DeFelice
(617) 398-5600 phone
155 Federal Street, Suite 400
Boston, MA 02110
john@blockesq.com

SOURCE: Block & Leviton LLP

ReleaseID: 504165

SAN DIEGO, CA / ACCESSWIRE / June 29, 2018 / Emerald Health Pharmaceuticals Inc. (EHP), which is developing medicines based on cannabinoid science, will present preclinical data on EHP-101, a patented synthetic cannabidiol (CBD)-derived new chemical entity (NCE), for the treatment of multiple sclerosis (MS) and scleroderma (SSc). A presentation and poster session will occur at the upcoming 28th Annual Symposium of the International Cannabinoid Research Society to be held on July 1- 4, 2018 in Leiden, Netherlands.

Details of the oral presentation are as follows:

Abstract Title: Effect of Oral VCE-004.8, A Cannabidiol Quinol Derivative On Experimental Autoimmune Encephalomyelitis
Lead Author: Carmen Navarrete, Ph.D.
Date and Time: July 3, 2018 at 9:30 AM CET
Location: Leidse Schouwburg Stadsgehoorzaal

Details of the poster session are as follows:

Abstract Title: Oral EHP-101 Alleviates Skin and Lung Fibrosis in Bleomycin Model of Scleroderma
Lead Author: Adela Garcia, Ph.D.
Date and Time: July 2, 2018 at 3:00 – 5:00 PM CET
Location: Leidse Schouwburg Stadsgehoorzaal

For more information about this conference, please visit: http://www.icrs2018.org/.

About EHP-101

EHP-101, also known in the scientific literature as VCE-004.8, is a patented aminoquinone NCE derived from CBD. It has been modified to enhance the therapeutic benefits of CBD by having a dual PPARγ and CB2 agonist activity, and also by affecting the hypoxia inducible factor (HIF) pathway. These receptors have been shown in the scientific literature to be beneficial in preventing neuroinflammation and demyelination in the central nervous system, and fibrogenesis in the periphery. EHP acquired VCE-004.8 from Vivacell Biotechnology España S.L. (Vivacell), a world leader in cannabinoid science located in Córdoba, Spain

About Emerald Health Pharmaceuticals Inc.

Emerald Health Pharmaceuticals is developing product candidates derived from cannabinoids for the treatment of CNS, autoimmune, and other diseases. The Company has two families of new chemical entities, based on CBD and cannabigerol (CBG) that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its first drug candidate, EHP-101, is focused on treating MS and SSc. Its second, EHP-102, is focused on treating Huntington’s disease and Parkinson’s disease. The company is advancing preclinical development with the intent to launch a Phase I clinical study in 2018. For more information, visit www.emeraldpharma.life or contact: info@emeraldpharma.life.

To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered “forward-looking statements,” as described in the private securities litigation reform act of 1995, that reflect management’s current beliefs and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in these presentations include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals’ investigational drug products have not been approved or cleared by the FDA.

SOURCE: Emerald Health Pharmaceuticals

ReleaseID: 504160

AUSTRALIA / ACCESSWIRE / June 29, 2018 / Bitfair, a Trading platform with the features capable of making it an upcoming generation thing, is about to launch (Pre-sale start date – July 9th, 2018). The platform allows its users to limit risks, trade with leverage and increase the returns. Ease of use and up to 1000X leverage are the main attention-grabbing aspects about Bitfair.

Let us brief you on what it is, how it works, how reliable it is and how capable it is.

What is Bitfair?

Bitfair is an OTC derivative exchange that allows the traders of the cryptocurrency to trade up to 1000X leverage. The Bitfair trading helps in making a profit during both up and down price movements of their favorite cryptocurrencies.

How Bitfair Works?

On this platform, all the traders get a chance for placing orders not for a single token but for different kinds of tokens in multiple Smart Option Contract trading indentures. The execution of this SOC trades will be implemented automatically, if, at any time, the up or down price is reached. Either during the contract period or at its expiry. As soon as the preset conditions are met, Bitfair will trigger and execute the trade. After this process, the funds will be dispersed to the profitable trader.

Is it Reliable?

This noble and exciting platform is a reliable platform for all traders trading in cryptocurrency that assists in removing all the issues that are related to real-time trading in a market. It allows overcoming all problems that are associated with traditional trading by using a peer-to-peer matching algorithm. Traders will have the ability to buy or short thus potentially profiting during up or down movement of a token price.

With this platform, the trader will get an opportunity to open both buy or short position orders for a variety of tokens at an astonishing 1000X leverage- which is about 10 times more than most of the exchanges and that too without the requirement of any broker.

Benefits of trading through Bitfair

1. Peer to peer trading

Because of Bitfair, you will get an opportunity to do peer to peer trading for your investments in cryptocurrency. No matter whether there is up or down movement of prices, traders always have the ability to profit.

2. Smart option contract

All the trade results are time stamped and are always published in SOC or smart option contract.

3. Indisputable proof

All the details of trading are recorded and are accessible with the help of public blockchain explorer.

4. Sale of token

All the users of the Bitfair platform possess the right to make pre-purchase of their Bitfair utility token and the token itself is tradable on the Bitfair exchange. All the fees of trading on Bitfair will be paid in XBF tokens whilst 50% is then burned by Bitfair when used.

Above points conclude into ‘Trading in Bitfair platform helps in doing trading with minimum risks, and maximum returns’, as experts believe.

To find out more, visit https://bitfair.com/

Read the white paper here

Join our Telegram community: t.me/bitfairhq

Media Contact:

Name: Magdel Steyn
Email: magdel@bitfair.com
Cell no.: +27 74 102 4851
Website: https://bitfair.com
TG Group Link: https://t.me/bitfairhq

SOURCE: Bitfair

ReleaseID: 504159

LOS ANGELES, CA / ACCESSWIRE / June 29, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: COOL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On June 25, 2018, Citron Research released a report accusing PolarityTE of being a “fraud.” The report alleges that the Company failed to disclose that the Company’s technology has been rejected by the U.S. Patent and Trademark Office. Based on this report, PolaryTE’s share price dropped significantly during intraday trading.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.

SOURCE: The Schall Law Firm

ReleaseID: 504164

RADNOR, PA / ACCESSWIRE / June 29, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Flex Ltd. (NASDAQ: FLEX) (“Flex”) investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of Flex Ordinary Shares between January 26, 2017 and April 26, 2018, inclusive (the “Class Period”).

Important Deadline Reminder: Investors who purchased Flex securities during the Class Period may, no later than July 9, 2018, seek to be appointed as a lead plaintiff representative of the class. For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/flex-ltd#join.

According to the complaint, Flex purportedly provides design, engineering, manufacturing, and supply chain services and solutions.

The Class Period commences on February 23, 2017, when Flex published a press release announcing its financial results for the quarter ended December 31, 2016.

According to the complaint, on April 26, 2018, Flex issued a press release disclosing that Flex’s Audit Committee, with the assistance of independent outside counsel, was investigating allegations by an employee that the company improperly accounted for obligations in a customer contract and certain related reserves.

Following this news, Flex’s share price fell $3.61 per share, or more than 21%, on high trading volume, to close at $13.03 per share on April 27, 2018.

The complaint alleges that, throughout the Class Period, the defendants failed to disclose that: (1) Flex’s internal controls over financial reporting were materially weak and deficient; (2) Flex had improperly accounted for obligations in a customer contract and certain related reserves; and, (3) as a result of the foregoing, Flex’s financial statements and the defendants’ statements about Flex’s business, operations, and prospects, were materially false and misleading at all relevant times.

If you wish to discuss this securities fraud class action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (888) 299–7706 or (610) 667–7706, or via e-mail at info@ktmc.com.

Flex investors may, no later than July 9, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 504148